Article Text

AB0558 What is the Prevalence of NON Criteria Antiphospholipid Antibodies in Patients with Antiphospholipid Syndrome?
  1. V. Rodríguez-García1,
  2. Y. Ioannou2,
  3. A. Fernández-Nebro1,
  4. D.A. Isenberg3,
  5. I. Giles3
  1. 1Servicio de Reumatología, Hospital Regional Universitario Carlos Haya, Málaga, Spain
  2. 2Centre for Adolescent Rheumatology
  3. 3Centre for Rheumatology, University College London Hospital, London, United Kingdom


Background Increasing interest has focussed upon assays which are not currently included in the Antiphospholipid syndrome (APS) classification criteria to detect antibodies directed against other phospholipids (PL), PL binding proteins and/or coagulation factors.

Objectives We carried out a systematic review to establish the prevalence of each non-criteria assay in APS and control populations.

Methods We searched PubMed and EMBASE using the keywords APS, antiphospholipid antibodies (aPL), non criteria, new assays, aCL, LA, anti-Domain I (aDI), anti-β2GPI, antiphosphatidylserine (aPS), antiphosphatidylethanolamine (aPE), antiphosphatidic acid (aPA), antiprothrombin (aPT), antiphosphatidylserine-prothtombin (aPS-PT), anti-cardiolipin/vimentin (CL/Vm) and Annexin A5 resistance (AnxA5R). Each publication was systematically examined.

Results We selected 14 (4 retrospective, 2 case-control and 8 cross-sectional) studies from which we were able to extract original data on prevalence of non-criteria aPL in 1307 patients with APS and 1612 disease controls and 625 healthy controls.

Conclusions The highest prevalence of non-criteria aPL in the largest number of patients with APS was found in studies of IgA anti β2GPI (56.33% in 229 APS patients), AnxA5R (53.37% in 163 APS patients) and IgG aDI (44% in 548 APS patients). All non-criteria aPL studied were found to be significantly raised in APS compared with controls. Most studies however, were confounded by: small sample size, retrospective collection; and different determination of positivity. Therefore, further prospective studies are urgently required to confirm these findings.


  1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH. 2006 Feb;4(2):295–306.

  2. Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013 Aug 1;122(5):817–24.

  3. Tincani A, Andreoli L, Casu C, Cattaneo R, Meroni P. Antiphospholipid antibody profile: implications for the evaluation and management of patients. Lupus. 2010 Apr;19(4):432–5.

  4. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul;42(7):1309–11.

  5. Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol. 2001 Sep;185(3):748–53.

  6. Lakos G, Kiss E, Regëczy N, Tarján P, Soltész P, Zeher M, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol. 1999 Sep;117(3):574–9.

  7. De Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IEM, et al. The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost JTH. 2009 Nov;7(11):1767–73.

Disclosure of Interest V. Rodríguez-García Grant/research support: FER grant from The Spanish Society of Rheumatology, Y. Ioannou: None declared, A. Fernández-Nebro: None declared, D. A. Isenberg: None declared, I. Giles: None declared

DOI 10.1136/annrheumdis-2014-eular.2749

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.